Access Keys:
Skip to content (Access Key - 0)

Fibrosarcoma

Tumor biology and incidence

  • Rare malignant spindle-cell neoplasm of mesenchymal origin
    • Accounts for fewer than 5% of bone sarcomas and 10% of all musculoskeletal sarcomas
  • Demonstrates fibroblastic differentiation and produces a collagen-rich fibrous tissue matrix
  • Spindle cells and matrix characteristically arranged as intersecting fascicles that form herringbone pattern
  • Differentiated from osteosarcoma by absence of osteoid production
  • Lacks the degree of pleomorphism and the bizarre cell typical of malignant fibrous histiocytoma of bone
  • At least 50% of tumors arise from metaphysis of distal femur or proximal tibia
  • Rarely, arises from surface of a bone; referred to as periosteal fibrosarcoma
  • May arise from underlying bone condition
    • Secondary to irradiation, Paget's disease, fibrous dysplasia, giant cell tumor, bone infarct, or chronic osteomyelitis
  • Multicentric lesions involving multiple bones rarely present at time of diagnosis

Age

  • Typically, patients older than age 50 years; however, wide range of ages has been observed, from children to older patients
  • Infantile form of fibrosarcoma exists (children <10yrs); has excellent prognosis when treated with adjuvant/neoadjuvant chemo and resection

Gender

M:F = 1:1

Presentation

  • Pain, localized tenderness and swelling
  • Restricted motion in the adjacent joint
  • Pathologic fracture (18% on initial presentation)

Plain films

  • Lesion usually purely lytic, permeative, or has a moth-eaten appearance
  • Arises eccentrically from metaphysis of bone extending into diaphysis
  • Cortical destruction and soft tissue extension usually evident
Site
  • Distal femur, proximal tibia, and pelvis
  • Few cases reported in humerus, scapula, hand, foot, radius, ribs, and spin
  • Location in bone: medullary versus periosteal, 2:1
Size
  • Variable
  • Usually larger than 5 cm
Tumor effect on bone
  • Lytic
  • Periosteal reaction, Codman's triangle, and hair-on-end patterns usually not present
  • No ossification or mineralization
Bone response to tumor
  • Permeative margin frequently observed
  • Sclerosis absent or scant
Matrix
  • Often totally radiolucent; no calcium or bone production
  • Dystrophic calcification may be seen
  • Background calcification/ossification of pre-existing lesion that has undergone sarcomatous degeneration may be present (such as bone infarct, Paget's disease)
Cortex
  • Cortical thinning and destruction
  • Periosteal reaction may be present; variable and generally less prominent than in osteosarcoma

Soft tissue mass

  • Commonly present
  • Can breach cortex and extend extraosseously into adjacent soft tissue
  • May also be seen as an isolated soft tissue lesion in the thigh or posterior knee arising deep to muscular fascia

Bone scan and chest CT

  • Nonspecific, but helpful in showing the extent of the lesion or the presence of additional sites of involvement
  • Necessary for systemic staging
  • Chest CT appropriate to rule out pulmonary metastases.

CT scan

  • Characterize extent of bony involvement, bone destruction, or bone reaction
  • Density of fibrosarcomas similar to that of surrounding normal muscle

MRI

Helps to define intraosseous spread and soft tissue extension or involvement of adjacent neurovascular structures

Differential diagnosis

  • Multiple myloma
  • Solitary metastasis
  • Malignant fibrous histiocytoma
  • Chondrosarcoma (dedifferentiated)
  • Ewing sarcoma (if less than 25 years old)
  • Giant cell tumor

Pathology

  • Gross: Tan to grayish white with rubbery consistency
  • Larger tumors may have myxoid, hemmorhagic, or necrotic foci
  • Microscopic: Varies with the level of differentiation
    • Well-differentiated, low-grade tumor
      • Homogeneous spindle-shaped fibroblasts with ovoid nuclei
      • Little pleomorphism
      • Infrequent mitoses
      • Prominent  herringbone pattern of fascicles of cells
    • Poorly differentiated, high-grade tumor
      • Pleomorphic cells
      • Abundant mitoses
      • Hyperchromic nuclei
      • Higher propensity for metastasizing early
  • Cellularity of tumor generally in inverse proportion to collagen production
  • IHC: Positive for vimentin, very weakly positive for smooth muscle actin
  • No definite etiology of fibrosarcoma known; genetic mutations likely play a role
  • Patients with multiple neurofibromas may have a 10% lifetime risk of developing fibrosarcoma

Diagnosis and treatment

  • Biopsy, in consultation with a musculoskeletal surgical oncologist
  • Tumor grade guides treatment regimen
    • Grade I tumor
      • Surgery, in many cases limb-sparing surgery (wide excision with reconstruction)
      • Survival rate: 80% at 10 years
    • Grade II tumor
      • Surgery plus adjuvant chemotherapy, although no definitive recommendations exist regarding chemotherapy for these intermediate-grade tumors
    • Grade III tumor
      • Induction chemotherapy, limb-sparing surgical resection, and postoperative chemotherapy. 
      • Overall 5-year survival rate ranges from 35% to 70%, depending on the study
  • Radiation usually administered only as a palliative measure for unresectable tumors or as a postoperative measure if margins were close or microscopically positive
  • Aggressive thoracotomy has been advocated for resection of pulmonary metastases (similar to treatment for osteosarcoma lung metastases)

Prognosis/outcome

  • Young age is favorable prognostic factor
    • According to Papagelopoulos et al, 5-year disease-free survival rate is 40% for patients 40 years or younger; only 12% for patients older than 40 years
  • Fibrosarcomas of bone carry worse prognosis than those of soft tissue
  • 15% local recurrence rate for surgically treated patients according to recent studies 
    • Univariate analysis of surgically treated patients: Age, location, grade, stage, surgical margins, and type of surgical procedure significantly affect disease-free survival and overall survival
  • Prognosis  most closely correlated with the grade of the tumor and presence of metastases at time of diagnosis
    • Patients with low-grade tumor have better survival rate than patients with a high-grade tumor
    • Overall survival rates at 5 years range from 28% to 34% for high-grade tumors and 50%-83% for low-grade tumors

Recommended reading

Papagelopoulos et al.  Primary Fibrosarcoma of Bone: Outcome after Primary Surgical Treatment.  CORR 2000 Apr;(373):88-103.

Wittig J. and Villalobos C.  Other Skeletal Sarcomas OKU 2 Musculoskeletal Tumors Ch19 pg 198-200.

Papagelopoulos et al.  Clinicopathologic Features, Diagnosis, and Treatment of Fibrosarcoma of Bone.  Am J Orthop 2002;31:253-257.

Peer Review

OrthopaedicsOne Peer Review Workflow is an innovative platform that allows the process of peer review to occur right within an OrthopaedicsOne article in an open, transparent and flexible manner. Learn more

Instructions for Authors

Read our Instructions for Authors to learn about contributing or editing articles on OrthopaedicsOne.

Content Partner

Learn about becoming an OrthopaedicsOne Content Partner.

Academic Resources

Resources on Fibrosarcoma from Pubget.

Error rendering macro 'rss' : The RSS macro is retrieving an HTML page.
Related Content

Resources on Fibrosarcoma and related topics in OrthopaedicsOne spaces.

Page: Fibrosarcoma (OrthopaedicsOne Articles)
Page: Ewing sarcoma (OrthopaedicsOne Articles)
Page: Osteosarcoma (OrthopaedicsOne Articles)
Page: Polyostotic conditions (OrthopaedicsOne Articles)
Page: Chondrosarcoma (central) (OrthopaedicsOne Articles)
Page: Malignant fibrous histiocytoma (MFH) (OrthopaedicsOne Articles)
Page: Adamantinoma (OrthopaedicsOne Articles)
Page: Parosteal osteosarcoma (OrthopaedicsOne Articles)
Page: Periosteal osteosarcoma (OrthopaedicsOne Articles)
Page: Myeloma (OrthopaedicsOne Articles)
Showing first 10 of 229 results